---
schema_version: "secwatch.filing_event.v1"
accession: "0001808665-23-000028"
form_type: "8-K"
ticker: "ASRT"
cik: "0001808665"
company_name: "Assertio Holdings, Inc."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T09:45:46.865536+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Assertio Q1 sales +18% to $41.8M; raises FY2023 outlook; plans Spectrum acquisition in Q3

## Summary
- Q1 net product sales $41.8M, up 18% YoY; GAAP net loss of $3.5M vs net income of $9.1M a year ago.
- Adjusted EBITDA $25.6M vs $23.9M YoY; adjusted EPS $0.29 vs $0.38.
- Full-year net product sales guidance raised to $157-167M; adjusted EBITDA guidance raised to $90-98M.
- Acquisition of Spectrum (all-stock + CVR) expected to close Q3 2023, accretive to adjusted EPS and cash flow in 2024.
- Converted $30M of convertible debt in Feb 2023, reducing outstanding debt by 43% and saving $2M annual interest.

## SEC filing metadata
- accession: 0001808665-23-000028
- form_type: 8-K
- ticker: ASRT
- cik: 0001808665
- company_name: Assertio Holdings, Inc.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808665/000180866523000028/0001808665-23-000028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808665/000180866523000028/asrt-20230509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001808665-23-000028
- JSON: https://secwatch.observer/filing/0001808665-23-000028.json
- Plain text: https://secwatch.observer/filing/0001808665-23-000028.txt

## Key facts
- Earnings Releases
  Assertio Holdings, Inc. reported the three months ended March 31, 2023 results: revenue $41.8 million, net income $(3.5) million, EPS $(0.07) per share. Guidance raised.
  - Period: the three months ended March 31, 2023
  - Revenue: $41.8 million
  - Net income: $(3.5) million
  - EPS: $(0.07) per share
  - Guidance: raised
  - Result: reported results
  source text: Adjusted Earnings Per Share (Non-GAAP) 1 $ 0.29 $ 0.38 First quarter results included the following as compared to the prior year quarter: • Net product sales increased 18%, to $41.8 million. ◦ Increased sales of Indocin and the addition of Sympazan more than offset expected declines in Cambia and Zipsor. ◦ Indocin sales increased 42%, primarily due to the transition
  evidence_url: https://www.sec.gov/Archives/edgar/data/1808665/000180866523000028/0001808665-23-000028-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.